Tuesday, 10 June 2014

So, http://pipeline.corante.com/archives/2014/06/10/right_to_try_here_we_go.php  is quite interesting; whilst I do think it is a bad plan for companies to be allowed to offer drugs post-Phase I at a profit, I wonder whether this doesn't have a useful upside in that drugs that only work against a subset of people with a particular condition often fail phase II because the overall effect isn't significant.
Having a wider range of patients take the drug outside phase II might give you some good hints as to whether your phase II isn't going well because your drug doesn't work, or whether it isn't going well because you have recruited the wrong patients.

On a lighter note, http://www.tonecartoons.co.uk/Shop/product/dalek-poppins/.

No comments:

Post a Comment